Cite
HARVARD Citation
Kazandjian, D. et al. (2016). Benefit‐Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration‐Positive, Metastatic Non‐Small Cell Lung Cancer. Oncologist. pp. 974-980. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Kazandjian, D. et al. (2016). Benefit‐Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration‐Positive, Metastatic Non‐Small Cell Lung Cancer. Oncologist. pp. 974-980. [Online].